Curricula Vitae

in alphabetischer Reihenfolge

**Paul Kosma**

**Date of Birth:** 12th October 1953

**Laboratory:**  Department für Chemie, Universität für Bodenkultur, A-1190 Wien, Austria

**Education:**

1979 - 1980: University of Technology-Vienna, PhD (Hons, first class), Organic Chemistry – *Heterocyclic chemistry*

1972 - 1977: University of Technology-Vienna, Diploma (Hons, first class), Technical Chemistry

**Academic Employment and major grants:**

Present position: Professor and Head of Department of Chemistry, Universität für Bodenkultur Wien (BOKU)

2006-2009 Scientific Director of Antiviral Spot of Excellence (ASPEX)-Vienna

1998-2006 Director of Christian-Doppler Laboratory of Pulp Reactivity

1990 Chair in Organic Chemistry, Universität für Bodenkultur Wien (BOKU)

1983 -1985: Postdoctoral Research with Frank Unger, SANDOZ Research Centre Vienna

1983 Postdoctoral Research, N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow

1980 - 1988: University Assistant at Institute of Chemistry, Universität für Bodenkultur Wien

1978 - 1980: Contract University Assistant position (part time), Institute of Organic Chemistry, TU Wien

## Major Research Interests

Chemistry and immunochemistry of bacterial polysaccharides and parasite glycans

Chemistry of triterpene glycosides

Chemistry of cellulose and hemicelluloses

>200 SCI-publications, 8 book chapters, 1 Book editorial (Anticarbohydrate Antibodies, Springer, 2012), 8 patents

## Memberships

Editorial Board Membership

*Innate Immunity*

*Carbohydrate Research*

National Representative of Austria

*European Carbohydrate Organization (2009-2011 President)*

*International Carbohydrate Organization (ICO)*

Member of European Polysaccharide Network of Excellence EPNOE (2005-2009)

**Scientific Societies**

Austrian Chemical Society (GÖCh)

Austrian Society for Biochemistry, Molecular Biology, Biotechnology and Genetics (ÖGMBT)

International Endotoxin and Innate Immunity Society

American Chemical Society

Board member of the Christian-Doppler-Research Society (2011-)

**Conference organization (chair**)

Japanese-European Workshop on Cellulose and Functional Polysaccharides (2005, Vienna)

9th European Workshop on Lignocellulosics and Pulp (2006, Vienna)

15th European Carbohydrate Symposium (July 19-24, 2009, Vienna)

**Tom Lillie, MD, PhD**

Tom Lillie, MD, PhD is the International Therapeutic Area Head for Oncology at Amgen, Inc. Tom is responsible for oncology clinical research in Phase 2 – phase 4 for the International region and oversees the clinical teams for Amgen programs in oncology and haematology.

Dr. Lillie completed his undergraduate degree in pharmacology, cell biology and immunology at Brasenose College, the University of Oxford, before earning his doctorate from the Department of Physiology at the University College of London. He then completed his medical education at the University College London Medical School, receiving honors distinction in clinical pharmacology and surgery. He is a member of the Royal College of Surgeons of England and the Faculty of Pharmaceutical Medicine of the Royal College of Physicians.

Dr. Lillie has held a variety of clinical research positions, specialising in oncology, in pharmaceutical companies in Europe and the USA.

**Contact Information:**

**Thomas Lillie, BA (hons) (Oxon), PhD, MD**

International Therapeutic Area Head for Oncology, Amgen

Amgen Ltd

1 Sanderson Road

Uxbridge

UB8 1DH

UK

Tel: +44 (0) 1895 525495

Fax: +44 (0) 1895 525112

Mob: +44 (0) 7590 96 11 99

Email: [tlillie@amgen.com](mailto:tlillie@amgen.com)

**Curriculum Vitae**

## Qualifications

**Dip Pharm Med** Dec 02 Pass – granted Membership of Faculty of Pharmaceutical Medicine, Royal College of Physicians

**MRCS (Eng)** June 98 Pass in final assessment Royal College of Surgeons

**MB, BS (hons)** July 95 Distinction in Clinical Pharmacology and Surgery

Certificate of Merit in Pathology

University College London Medical School

Top Distinction in 1st BM (Pre-clinical)

Brasenose College, University of Oxford

**PhD** Sept 92 The Role of GTP-binding Proteins in Exocytosis

Supervisor: Professor B.D. Gomperts

Department of Physiology

University College London

**BA (Hons)** June 89 1st Class honours

Pharmacology, Cell Biology + Immunology.

Final Honour School of Physiological Sciences

Brasenose College, University of Oxford

**Academic Prizes and Awards**

July 95 1st Zeneca, Hobbiger & Flintnan prize in Clinical Pharmacology

Oct 94 Amulree elective bursary.

Aug 94 2nd Cilay project prize in General Practice.

Aug 93 Macgrath prize for best overall performance in 1st clinical year.

Aug 93 Certificate of Merit for 1st year assessment.

June 89 Prize for 1st class honours.

April 88 Prize for top Distinction in 1st B.M.

April 88 Elected to Open Scholarship, Brasenose College, Oxford

Oct 87 Elected to Open Exhibition, Brasenose College, Oxford

## Employment

**Sept 2008 – present International Therapeutic Area Head**

International therapeutic area head for Oncology. Leading a team of 15 people covering 4 marketed products and 7 pipeline programs. Responsible for oversight of research and development activities in International Region, interface with leadership of Global Development organisation, co-chair of International Oncology Business Team. Successfully implemented new global medical structure in International region.

**Nov 2007 – Sep 2008 Global Product Area Lead**

**Aug 2005 – Oct 2007 Global Development Leader**

Global Product Area Lead for Aranesp Oncology and a phase 2 therapeutic molecule. Leading a team of health care professionals in the planning and execution of the clinical program for Aranesp® and providing oversight to registration and non-registration clinical research programs (phase 2 – phase 4). Co-chair of the Product Strategy Team, responsible for creation and execution of the global strategic plan for the product. Leadership of cross-functional clinical team including medical communication, regional medical liaisons, marketing, regulatory, Health Economics, biostatistics, data management and clinical operations for Global Clinical Development. Engagement with thought leaders in the medical oncology and academic community, including projects with cooperative research groups in developing and implementing cooperative group clinical studies. Design and implementation of paediatric studies (to fulfil post-marketing commitments) with paediatric oncology groups in US and EU. Development of working relationships with members of the medical, regulatory, patient advocacy and academic communities. Planning and execution of investigator meetings and advisory panels on a variety of topics including clinical strategy and future clinical trials. Scientific presentations to regulatory agencies, scientific bodies, healthcare organisations, professional societies and foundations. Management of complex relationship with licensee companies for safety / regulatory interactions.

**Nov 2004 – Aug 2005 Director, Amgen Inc, California**

Medical Director for denosumab in oncology. Championed clinical and commercial opportunity for this molecule with Global Commercial team and set strategic direction for the development program as part of the global Product Strategy Team. This resulted in winning development and commercial review board approval for an extensive phase 3 programme in oncology. I initiated formation of the medical affairs team and led medical affairs activities.

**Aug 2002 – Nov 2004 Medical Affairs Manager Oncology, Amgen Ltd, UK**

Member of the leadership team of the oncology business unit, with a matrix management structure. Line management of 2 nurse advisors, 2 medical advisors and 2 scientific advisors. Business focussed on promotion of growth factor usage for support of patients undergoing chemotherapy in a wide range of tumours. Medical leadership of the successful launch of 2 new products. Leadership of team producing NICE submission. Member of European Business Team, setting European clinical and business strategy, responsible for European budget, setting and achieving European corporate goals.

**June 2001 – Aug 2002 Senior Medical Advisor, Aventis Pharma**

**April 2000 – June 2001** **Medical Advisor, Aventis Pharma**

This broad based medical advisor role allowed to me to rapidly assimilate both knowledge and experience of the pharmaceutical industry. I was responsible for the cardiovascular, CNS and OTC product portfolios. I gained experience in clinical trials, medical marketing, health outcomes (2 NICE submissions), safety and regulatory.

**Post Graduate Education**

Amgen Executive Leadership Development Programme – Nov 2006 + Sept 2007

Amgen Management Development Programme, Jan 2003 – Aug 2003

Postgraduate Course in Pharmaceutical Medicine, University of Wales

Strat-X marketing strategy course – September 2001

CPMP New Entrants Training Day

Specialist Registrar skills in general surgery – Feb 1999, RCS, London

R.C.S. Basic Surgical Skills course - July 1997, St Mary’s Hospital, London

M.R.C.S. S.T.E.P. course (involved in the pre-publication testing of the course material)

A.T.L.S. - November 1996 - pass with commendation

**Clinical Posts**

Specialist Registrar

###### Oct 1998 – April 2000 Wessex Region Rotation in General Surgery

General surgical rotation with special interest in surgical oncology (breast and colorectal cancer). Multi-disciplinary team working with medical oncologists and radiotherapists. Experience in vascular, urology, trauma and plastic surgery.

#### Senior House Officer

#### Aug 1996 – Sept 1998

Posts in A+E (Kings College Hospital) and vascular (St Mary’s Hospital). Surgical rotation at UCL hospitals including trauma + orthopaedics, general, plastic, urological and cardiothoracic surgery.

**Pre-Registration House Officer**

**Aug 1995 – July 1996**

General surgery, urology + ENT – UCL hospitals.

General Medicine + endocrinology - Mayday University Hospital.

## Research

**PhD** The Role of GTP-binding proteins in exocytosis

My research centred around the role of GTP-binding proteins (G-proteins) in the regulation of exocytotic secretion. At least two types of G-proteins exist. Heterotrimeric (large) G-proteins, linking cell surface receptors to intracellular effectors and monomeric (small) G-proteins regulating cell division, cytoskeleton and intracellular transport. My work focused on mast cells, which secrete histamine in response to crosslinking of IgE receptors, seen most dramatically in anaphylaxis.

By using a permeabilised cell system I was able to demonstrate that this process depends not only on calcium, but also on G-proteins. Both classes of G-protein appear to be involved in regulating exocytosis and this mechanism appears to be similar for neutrophils, eosinophils and platelets. These findings extend the role of G-proteins in inflammation and healing to include secretion from myeloid cells as well as control of cell division and generation of inflammatory mediators.

**BA(Hons)** Dissertation: Purification of soluble CD4

Supervisor: Professor A.F. Williams, MRC Immunology Unit,

Sir William Dunn School of Pathology, University of Oxford

CD4 is a TH cell marker and is also the receptor for HIV. This project succeeded in purifying CD4 expressed in a cell line from contaminants in the culture medium. The purified protein was used to investigate the 3-D structure of CD4 and its interaction with HIV.

## Publications

Robert Pirker, Rodryg A. Ramlau, Wolfgang Schuette, Petr Zatloukal, Irene Ferreira, **Tom Lillie**, and Johan F. Vansteenkiste 2008 Safety and Efficacy of Darbepoetin Alfa in Previously Untreated Extensive-Stage Small-Cell Lung Cancer Treated With Platinum Plus Etoposide. JCO 26: 2342-2349

Robert E. Smith Jr, Matti S. Aapro, Heinz Ludwig, Tamas Pinter, Martin Smakal, Tudor E. Ciuleanu, Li Chen, **Tom Lillie**, and John A. Glaspy 2008 Darbepoetin Alfa for the Treatment of Anemia in Patients With Active Cancer Not Receiving Chemotherapy or

Radiotherapy: Results of a Phase III, Multicenter,Randomized, Double-Blind, Placebo-Controlled Study. JCO 26:1040-1050

**Lillie THW**, Whalley TD, Gomperts BD 1991 Modulation of the exocytotic reaction of permeabilised rat mast cells by ATP, other nucleotides and Mg2+. Biochim Biophys Acta 1094: 355‑363

**Lillie THW**, Gomperts BD 1992 Guanine nucleotide is essential, Ca2+ is a modulator, in the exocytotic reaction of permeabilised rat mast cells. Biochem J 288: 181‑187

**Lillie THW**, Gomperts BD 1993 Kinetic characterisation of guanine nucleotide induced exocytosis from permeabilised rat mast cells. Biochem J 290: 389‑394

**Lillie THW**, Gomperts BD 1993 A cell physiological description of G‑E, a

GTP‑binding protein that mediates exocytosis. In: "The GTPase

Superfamily" F McCormick, Ed, Ciba Foundation Symposium, Wiley, Chichester, UK, 176: 164‑184

**Lillie THW**, Gomperts BD 1992 GTP, ATP, Ca2+ and Mg2+ as effectors and modulators of exocytosis in permeabilised rat mast cells. Phil Trans Roy Soc Lond B 336: 25‑34

**Lillie THW**, Gomperts BD 1993 GTPases as regulators of regulated exocytosis. In: "GTPases in Biology" B Dickey, L Birnbaumer, Eds, Springer, Berlin, Germany, pp 661‑677

Gomperts BD, Churcher Y, Koffer A, Kramer IM, **Lillie THW**, Tatham PER 1990 The role and mechanism of the GTP‑binding protein, GE in the control of regulated exocytosis. Biochem Soc Symp 56: 85‑101

Gomperts BD, Churcher Y, Koffer A, **Lillie THW**, Tatham PER, Whalley TD 1991 Regulated exocytosis as a paradigm of biological signal transduction. NATO ASI series (Springer Verlag) H52: 459‑473

Gomperts BD, Churcher Y, Koffer A, **Lillie THW**, Tatham PER, Whalley TD 1991 Intracellular mechanisms regulating exocytotic secretion in mast cells. Int Archs Allergy appl Immunol 94: 38‑46

## Other Interests

Sailing Cabinet Making

Cycling Playing guitar Restoring Victorian Houses

**Renée Schroeder**

**Univ.-Prof.in Dr.in Renée Schroeder, Universität Wien, Max F. Perutz Laboratories, Institut für Biochemie und Molekulare Zellbiologie**

geboren 1953 in Joao Monlevade, Brasilien  
1967: Übersiedlung nach Bruck an der Mur, Österreich  
Kinder: Fabian (1983), Constantin (1985)

**Ausbildung**

|  |  |  |  |
| --- | --- | --- | --- |
| Universität Wien | Biochemie | Mag.rer.nat | 1972-1978 |
| Universität Wien | Biochemie | Dr.rer.nat | 1978-1981 |
| LMU, MÜnchen, DE | Post-doc | | 1972-1978 |
| CNRS, Gif/Yvette, FR | Post-doc, EMBO Stipendium | | 1982-84-85 |
| Wadsworth Center, New York, USA | Post-doc, Schrödinger Stipendium | | 1987-1989 |
| Universität Wien | Habilitation in Genetik | | 1993 |

**Beruflicher Werdegang**

|  |  |
| --- | --- |
| seit 2006 | Professur für RNA-Biochemie, Universität Wien |
| 1995-2004 | Ao. Prof. Institut für Mikrobiologie und Genetik, Universität Wien |
| 1989-2004 | Gruppenleiterin am Institut für Mikrobiologie und Genetik, Universität Wien |

**Ausgewählte Publikationen**

1. von AHSEN,U, DAVIES,J. and SCHROEDER,R. (1991) Antibiotic inhibition of group I ribozyme function. Nature 353: 368-370
2. WALLIS,M.G., von AHSEN,U., SCHROEDER,R. and FAMULOK,M (1995) A novel RNA motif for neomycin recognition. Chemistry & Biology 2, 543-552
3. WALDSICH,C., GROSSBERGER,R., and SCHROEDER,R. (2002) RNA chaperone StpA loosens interactions of the tertiary structure in the td group I intron. Genes & Dev. 16, 2300-2312.
4. AMERES, S.L., MARTINEZ, J. and SCHROEDER, R. Molecular basis for RISC mediated target recognition and cleavage. Cell (2007) 130, 101-112.
5. LORENZ, C., GESELL, T., ZIMMERMANN, B., SCHOEBERL, U.E., BILUSIC, I., RAJKOWITSCH, L. WALDSICH, C., von HAESELER, A. and SCHROEDER, R. Genomic SELEX for Hfq-binding RNAs identifies genomic aptamers predominantly in antisense transcripts. Nucleic Acids Res. (2010) 38, 3794-3808.

**Synergistische Aktivitäten**

1. Öffentliche Funktionen  
   Österreichische Delegierte beim EMBO council (1998-2004)  
   Mitglied der Bioethikkommission (2001–2005)  
   Vizepräsidentin des Österreichischen Wissenschaftsfonds FWF (2005-2010)  
   Mitglied des Rates für Forschung und Technologieentwicklung (2010-bis jetzt)
2. Akademischen Funktionen  
   Vorsitzenden der Studienkommission für Molekularbiologie (1999-2002);  
   Vizedekanin der Fakultät für Lebenswissenschaften (2004-2006).
3. Editorial  
   Editor in Chief of [RNA Biology](http://www.landesbioscience.com/journals/rnabiology/) (2007 bis jetzt)
4. Nachwuchsförderung [VIPS Programm](http://www.projects.mfpl.ac.at/vips/)

**Auszeichnungen**

|  |  |
| --- | --- |
| 1984 | Theodor-Körner Stiftungspreis für Wissenschaft und Kunst |
| 1992 | SANDOZ "Forschungspreis für Biologie" |
| 1997 | Mitglied von EMBO |
| 2001 | L'Oréal UNESCO Special Award for Women in Science |
| 2002 | korrespondierendes Mitglied der Österreichischen Akademie der Wissenschaften |
| 2002 | Wissenschaftler des Jahres |
| 2003 | wirkliches Mitglied der Österreichischen Akademie der Wissenschaften |
| 2003 | Wittgenstein Preis |
| 2005 | Preis der Stadt Wien für “Natur- und Technische Wissenschaften” |
| 2006 | „Großes Ehrenzeichnen für Verdienste um die Republik Österreich“ |
| 2007 | „Frauenpreis“ Stadt Wien |
| 2011 | Eduard Buchner Preis |